Latest period
$219M
YoY change
+143.5%
5Y CAGR
-3.9%
Peak year (FY2021)
$208M
Latest annual
$86.5M
Total Equity history chart for Relmada Therapeutics (RLMD) from 2017 to 2025
Latest: $86.5M
Total Equity growth chart for Relmada Therapeutics (RLMD) from 2017 to 2025
Latest: +143.5%
Total Equity history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| FY2025 | $86.5M | +143.5% | +$51M | ||
| FY2024 | $35.5M | -58.4% | -$49.8M | ||
| FY2023 | $85.4M | -39.2% | -$55.1M | ||
| FY2022 | $140M | -32.6% | -$67.8M | ||
| FY2021 | $208M | +97.3% | +$103M | ||
| FY2020 | $106M | -8.7% | -$10.1M | ||
| FY2019 | $116M | +1419.4% | +$108M | ||
| FY2018 | $7.61M | -238.1% | +$13.1M | ||
| FY2017 | -$5.51M | -477.5% | -$6.97M | ||
| FY2016 | $1.46M | -79.3% | -$5.58M | ||
| FY2015 | $7.04M | -20.1% | -$1.77M | ||
| FY2014 | $8.81M | -115.9% | +$64.1M | ||
| FY2013 | -$55.3M | -486761.5% | -$55.3M | ||
| FY2012 | $11.4K | — | — |
- FY2025$86.5M+143.5%
- FY2024$35.5M-58.4%
- FY2023$85.4M-39.2%
- FY2022$140M-32.6%
- FY2021$208M+97.3%
- FY2020$106M-8.7%
- FY2019$116M+1419.4%
- FY2018$7.61M-238.1%
- FY2017-$5.51M-477.5%
- FY2016$1.46M-79.3%
- FY2015$7.04M-20.1%
- FY2014$8.81M-115.9%
- FY2013-$55.3M-486761.5%
- FY2012$11.4K—
Total Equity values are taken from Relmada Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's latest reported total equity is $219M. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Relmada Therapeutics (RLMD) total equity is $86.5M – surged 143.5% year-over-year.
Relmada Therapeutics total equity compound annual growth for the 2020–2025 (5 years) window is -3.9%, with a net decline across the window.
Relmada Therapeutics total equity plunged from $208M in 2021 to $86.5M in 2025, a 58.5% drawdown.
Across the available history, total equity reached its high of $208M in 2021 and its low of -$55.3M in 2013.
Relmada Therapeutics Total Equity by Year
Relmada Therapeutics Total Equity 2025: $86.5M
Relmada Therapeutics posted total equity of $86.5M in 2025, surged 143.5% from 2024.
Relmada Therapeutics Total Equity 2024: $35.5M
In 2024, Relmada Therapeutics reported total equity of $35.5M, plunged 58.4% below 2023.
Relmada Therapeutics Total Equity 2023: $85.4M
Relmada Therapeutics total equity in 2023 was $85.4M, plunged 39.2% below 2022.
Relmada Therapeutics Total Equity 2022: $140M
2022's total equity for Relmada Therapeutics came in at $140M, plunged 32.6% below 2021.
Relmada Therapeutics Total Equity 2021: $208M
Relmada Therapeutics total equity in 2021 was $208M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Total Equity
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest total equity
| $94.1B | |
| $81.5B | |
| $53.4B | |
| $52.6B | |
| $30.5B | |
| $26.5B | |
| $8.66B | |
| -$3.27B |
- $94.1B
- $81.5B
- $52.6B
- $30.5B
- $26.5B
- $8.66B
- -$3.27B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.